MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Type of Assessment:

Establishment and characterization of a new malignant peritoneal mesothelioma cell line, KOG-1, from the ascitic fluid of a patient with pemetrexed chemotherapy resistance.

Human Cell 2019 October 3 [Link] Akahane T, Hirasawa A, Imoto I, Okubo A, Itoh M, Nanki Y, Yoshihama T, Tominaga E, Aoki D Abstract Malignant peritoneal mesothelioma (MPeM) is a rare and aggressive form of malignant mesothelioma. Sufficient biological tools for studying the functional characteristics of this cancer have not been developed. Therefore, in […]

October 16, 2019

Chemotherapy, Full Archive, Pemetrexed (Alimta), Peritoneal (Abdominal Mesothelioma)
Comments Off on Establishment and characterization of a new malignant peritoneal mesothelioma cell line, KOG-1, from the ascitic fluid of a patient with pemetrexed chemotherapy resistance.

Can novel adipokines, asprosin and meteorin-like, be biomarkers for malignant mesothelioma?

Biotechnic & Histochemistry 2019 October 1 [Link] Kocaman N, Artaş G Abstract Malignant mesothelioma (MM) is a rare tumor of serous surfaces that has a poor prognosis. Cancer is a multistage process by which cells undergo metabolic and behavioral changes that cause excessive and untimely proliferation. Asprosin (ASP) and meteorin-like (METRNL) are two peptides associated […]

October 15, 2019

Biomarkers, Full Archive, Immunohistochemistry or IHC
Comments Off on Can novel adipokines, asprosin and meteorin-like, be biomarkers for malignant mesothelioma?

Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma.

Modern Pathology 2019 September 30 [Link] Brich S, Bozzi F, Perrone F, Tamborini E, Cabras AD, Deraco M, Stacchiotti S, Dagrada GP, Pilotti S Abstract The aim of this study was to assess the performance of fluorescence in situ hybridization (FISH) in identifying the copy number profiles of the three key peritoneal mesothelioma tumor suppressor […]

October 14, 2019

Full Archive, Immunohistochemistry or IHC, Peritoneal (Abdominal Mesothelioma)
Comments Off on Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma.

Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma.

Modern Pathology 2019 September 30 [Link] Brich S, Bozzi F, Perrone F, Tamborini E, Cabras AD, Deraco M, Stacchiotti S, Dagrada GP, Pilotti S Abstract The aim of this study was to assess the performance of fluorescence in situ hybridization (FISH) in identifying the copy number profiles of the three key peritoneal mesothelioma tumor suppressor […]

October 11, 2019

Full Archive, Immunohistochemistry or IHC, Peritoneal (Abdominal Mesothelioma)
Comments Off on Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma.

Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma.

Cancer Management and Research 2019 September 24 [Link] Walter RFH, Sydow SR, Berg E, Kollmeier J, Christoph DC, Christoph S, Eberhardt WEE, Mairinger T, Wohlschlaeger J, Schmid KW, Mairinger FD Abstract BACKGROUND: Bortezomib is an approved proteasome inhibitor for the treatment of certain lymphoma subtypes. Two clinical trials investigated bortezomib in patients with malignant pleural […]

October 10, 2019

Cisplatin (Platinol ®), Full Archive, Pleural
Comments Off on Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma.

Malignant mesothelioma in construction workers: the Apulia regional mesothelioma register, Southern Italy.

BMC Research Notes 2019 September 30 [Link] Vimercati L, Cavone D, Caputi A, Delfino MC, De Maria L, Ferri GM, Serio G Abstract OBJECTIVE: Asbestos was widely used in construction in both a friable and a compact form until the 1990s, before its use was banned. Today, many of these materials are still in situ […]

October 8, 2019

Epithelioid, Full Archive, Occupational Asbestos Exposure, Pleural
Comments Off on Malignant mesothelioma in construction workers: the Apulia regional mesothelioma register, Southern Italy.

Volumetric Modulated Arc Therapy After Lung Sparing Surgery for Malignant Pleural Mesothelioma: A Single Institution Experience.

Clinical Lung Cancer 2019 September 5 [Link] Franceschini D, De Rose F, Cozzi S, Renna I, Franzese C, Di Brina L, Navarria P, D’Agostino GR, Mancosu P, Tomatis S, Scorsetti M Abstract INTRODUCTION: We investigated the possible role of volumetric modulated arc therapy (VMAT) in the setting of adjuvant treatment of malignant pleural mesothelioma (MPM) […]

October 1, 2019

Carboplatin, Cisplatin (Platinol ®), Full Archive, Pleural, Pleurectomy/decortication, Radiotherapy
Comments Off on Volumetric Modulated Arc Therapy After Lung Sparing Surgery for Malignant Pleural Mesothelioma: A Single Institution Experience.

Expression of FGFR1-4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity.

Cells 2019 September 16 [Link] Vlacic G, Hoda MA, Klikovits T, Sinn K, Gschwandtner E, Mohorcic K, Schelch K, Pirker C, Peter-Vörösmarty B, Brankovic J, Dome B, Laszlo V, Cufer T, Rozman A, Klepetko W, Grasl-Kraupp B, Hegedus B, Berger W, Kern I, Grusch M Abstract Malignant pleural mesothelioma (MPM) is a devastating malignancy with […]

September 26, 2019

Full Archive, Immunohistochemistry or IHC, Pleural
Comments Off on Expression of FGFR1-4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity.

The Role of Immunohistochemistry Studies in Distinguishing Malignant Mesothelioma from Metastatic Lung Carcinoma in Malignant Pleural Effusion.

Iranian Journal of Pathology Spring 2019 [Link] Halimi M, BeheshtiRouy S, Salehi D, Rasihashemi S Abstract BACKGROUND AND OBJECTIVE: Early diagnosis of malignant pleural mesothelioma (MPM) is the key point of its treatment. The main problem is the precise diagnosis of mesothelioma and its differentiation from metastatic lung adenocarcinoma. Mesothelioma exhibits complex immunohistochemical characteristics. The […]

September 25, 2019

Diagnosis & Differentiation, Full Archive, Immunohistochemistry or IHC, Pleural
Comments Off on The Role of Immunohistochemistry Studies in Distinguishing Malignant Mesothelioma from Metastatic Lung Carcinoma in Malignant Pleural Effusion.

Malignant Mesothelioma: Has Anything Changed?

Seminars in Respiratory and Critical Care Medicine 2019 June [Link] Kim RY1, Sterman DH2, Haas AR3 Abstract Malignant pleural mesothelioma is a rare cancer associated with asbestos exposure and portends a dismal prognosis. Its worldwide incidence has been increasing, and treatment options are currently suboptimal and noncurative. However, since the turn of the century, several […]

September 23, 2019

Cisplatin (Platinol ®), Environmental Asbestos Exposure, Full Archive, Occupational Asbestos Exposure, Pemetrexed (Alimta), Pleural
Comments Off on Malignant Mesothelioma: Has Anything Changed?